Astellas Pharma Inc (ALPMY)
9.42
+0.15
(+1.60%)
USD |
OTCM |
Apr 16, 09:48
Astellas Pharma Revenue (Quarterly): 2.858B for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.858B |
| September 30, 2023 | 2.715B |
| June 30, 2023 | 2.733B |
| March 31, 2023 | 2.682B |
| December 31, 2022 | 2.853B |
| September 30, 2022 | 2.754B |
| June 30, 2022 | 2.947B |
| March 31, 2022 | 2.616B |
| December 31, 2021 | 2.996B |
| September 30, 2021 | 2.957B |
| June 30, 2021 | 2.980B |
| March 31, 2021 | 2.914B |
| December 31, 2020 | 3.116B |
| September 30, 2020 | 2.907B |
| June 30, 2020 | 2.853B |
| March 31, 2020 | 2.868B |
| December 31, 2019 | 3.109B |
| September 30, 2019 | 2.949B |
| June 30, 2019 | 3.040B |
| March 31, 2019 | 2.736B |
| December 31, 2018 | 3.175B |
| September 30, 2018 | 2.853B |
| June 30, 2018 | 3.017B |
| March 31, 2018 | 2.776B |
| December 31, 2017 | 3.185B |
| Date | Value |
|---|---|
| September 30, 2017 | 2.860B |
| June 30, 2017 | 2.903B |
| March 31, 2017 | 2.692B |
| December 31, 2016 | 3.243B |
| September 30, 2016 | 3.067B |
| June 30, 2016 | 3.127B |
| March 31, 2016 | 2.665B |
| December 31, 2015 | 3.113B |
| September 30, 2015 | 2.814B |
| June 30, 2015 | 2.833B |
| March 31, 2015 | 2.472B |
| December 31, 2014 | 3.133B |
| September 30, 2014 | 2.880B |
| June 30, 2014 | 2.889B |
| March 31, 2014 | 2.641B |
| December 31, 2013 | 3.228B |
| September 30, 2013 | 2.777B |
| June 30, 2013 | 2.729B |
| March 31, 2013 | 2.462B |
| December 31, 2012 | 3.428B |
| September 30, 2012 | 2.971B |
| June 30, 2012 | 3.034B |
| March 31, 2012 | 2.594B |
| December 31, 2011 | 3.618B |
| September 30, 2011 | 2.989B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
2.616B
Minimum
Mar 2022
3.116B
Maximum
Dec 2020
2.887B
Average
2.907B
Median
Sep 2020
Revenue (Quarterly) Benchmarks
| Daiichi Sankyo Co Ltd | 3.027B |
| Takeda Pharmaceutical Co Ltd | 7.526B |
| Nxera Pharma Co Ltd | 49.39M |
| PeptiDream Inc | 41.78M |
| Stemcell Holdings Inc | 3.403M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 98.29M |
| Total Expenses (Quarterly) | 2.730B |
| EPS Diluted (Quarterly) | 0.0546 |
| Enterprise Value | 20.78B |
| Gross Profit Margin (Quarterly) | 82.01% |
| Profit Margin (Quarterly) | 3.44% |
| Earnings Yield | -0.09% |
| Operating Earnings Yield | 0.41% |
| Normalized Earnings Yield | -0.3951 |